Nav: Home

Botox may beat neural stimulation for urge incontinence, but has risks

October 04, 2016

DURHAM, N.C. -- When women suffer from bladder incontinence, the urge to urinate can come on suddenly and sometimes uncontrollably, leading to leakage. Patients looking for relief can initially opt for first- and second-line therapies such as drinking fewer liquids or caffeinated beverages, pelvic floor muscle training, and medication.

If those treatments prove inadequate however, patients may seek more invasive options, including a form of nerve stimulation called sacral neuromodulation (an implanted device sold as InterStim), or a bladder injection of botulinum toxin, which is sold as Botox.

A head-to-head comparison of sacral neuromodulation and botulinum toxin led by a Duke Health researcher shows that Botox provides more daily relief for women, but might also be associated with more adverse events.

The findings are to be published Oct. 4 in the Journal of the American Medical Association (JAMA).

An injection of botulinum toxin in the bladder muscle works to address urgency urinary incontinence by relaxing the overactive bladder muscles that cause the condition. A sacral neuromodulation implant does the same thing by sending electrical pulses to nerves in the spine.

"Urgency urinary incontinence is common, with 17 percent of women over age 45 and 25 percent of women over age 75 suffering from it," said Cindy L. Amundsen, M.D., the study's lead author and the Roy T. Parker Professor of Obstetrics and Gynecology at Duke University School of Medicine. "That's why it's important for both patients and health care providers to have information that can guide their choice between these two therapies."

The study involved 381 women from nine U.S. medical centers who recorded at least six urgency incontinent episodes over three consecutive days and had not improved with other treatments.

The participants were randomly assigned to either receive sacral neuromodulation or a 200-unit injection of botulinum toxin. After a trial period to test their responsiveness to the therapies, 364 women were enrolled and followed for six months after treatment.

The study team analyzed the number of urgency incontinent episodes on monthly "bladder diaries." Participants who received botulinum toxin saw their number of daily urgency incontinent episodes decrease by 3.9 on average versus 3.3 on average in the sacral neuromodulation group. The difference was statistically significant.

Botulinum toxin participants also reported a greater reduction in bothersome symptoms, higher satisfaction with treatment, and a greater likelihood of endorsing the treatment.

Additionally, among participants who completed at least four monthly diaries, a higher percentage of botulinum toxin participants saw at least a 75-percent reduction in or complete resolution of urgency incontinent symptoms.

However, the Botox patients also had three times the rate of urinary tract infections. Some botulinum toxin participants also required intermittent self-catheterization, although at lower rates than reported in previous studies using this dose.

For the sacral neuromodulation participants, the most common adverse event was removal or revision of the implant during the six months. This occurred at a low rate, similar to previous studies.

"This study is valuable because it is the first randomized trial comparing the efficacy of two FDA-approved, third-line therapies in a severely affected population," Amundsen said. "The information should help guide care."

While the study did not compare the cost of the two treatments, Amundsen noted that patients who receive botulinum toxin may require additional injections as part of continued treatment. Additionally, the study only takes Botox into account and no conclusions can be drawn for other botulinum toxin preparations that may be used to treat urgency incontinence.
-end-
In addition to Amundsen, co-authors include Holly E. Richter, Shawn A. Menefee, Yuko M. Komesu, Lily A. Arya, W. Thomas Gregory, Deborah L. Myers, Halina M. Zyczynski, Sandip Vasavada, Tracy L. Nolen, Dennis Wallace, and Susan F. Meikle.

The study was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the NIH Office of Research on Women's Health at National Institutes of Health 3316 (U01 HD41249U10, HD41261U10, HD41267, U10 HDS4215U10-HD41261-11, U10-HD069013, U10-HD054214-06, U10-HD054215-06, U10-HD041267-l2, U10-HD069025-01, U10-HD069010, U10-HD054136, U10-HD05424l, and U10-HD04l250-11).

One co-author reported financial relationships with the commercial makers of both InterStim and Botox. Full disclosures are available in the study's manuscript.

Duke University Medical Center

Related Botulinum Articles:

New insights into the toxin behind tetanus
Tetanus toxin is the neurotoxin that causes lockjaw. Many are vaccinated, but tetanus still kills tens of thousands of people per year worldwide.
TSRI scientists find simple copper complex shuts down botulinum neurotoxin poisoning
Clostridium botulinum is the bacterium that causes the neurointoxication, which produces one of the most potent toxins on earth and is classified as a potential bioterrorism threat.
More than $16 billion spent on cosmetic plastic surgery
A new report from the American Society of Plastic Surgeons reveals that Americans spent more than ever before -- $16 billion -- on cosmetic plastic surgery and minimally invasive procedures in 2016.
Botox may beat neural stimulation for urge incontinence, but has risks
A head-to-head comparison of sacral neuromodulation and botulinum toxin led by a Duke Health researcher shows that Botox provides more daily relief for women suffering from urgency urinary incontinence, but might also be associated with more adverse events.
Botulinum neurotoxin in plastic surgery -- what's the evidence for effectiveness?
Botox and other botulinum neurotoxin (BoNT) products are widely known for their use in treating facial wrinkles -- but they can also be used to treat a wide range of non-cosmetic problems.
DFG awards prize for alternative to animal experiments
The German Research Foundation will award the Ursula M. Händel Animal Welfare Prize for the sixth time this year.
Botulinum toxin study proves possibility of remote effects
The botulinum toxins are among the deadliest substances on Earth, and two specific toxins -- including the popular drug Botox -- have multiple uses for treating many neuromuscular conditions, including frown lines, disabling muscle spasms and migraine headaches.
AAN updates guidelines: Botulinum toxin for spasticity, headache, other brain disorders
The American Academy of Neurology has updated its 2008 guidelines on the use of botulinum toxin for spasticity, cervical dystonia, blepharospasm and migraine headache, based on recent research.
Botulism in waterbirds: Mortality rates and new insights into how it spreads
Outbreaks of botulism killed large percentages of waterbirds inhabiting a wetland in Spain.
LSU Health New Orleans technology part of $90 million pharma deal
A technology invented by faculty at LSU Health New Orleans is part of an acquisition deal by Allergan plc, a global pharmaceutical company.

Related Botulinum Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Don't Fear Math
Why do many of us hate, even fear math? Why are we convinced we're bad at it? This hour, TED speakers explore the myths we tell ourselves and how changing our approach can unlock the beauty of math. Guests include budgeting specialist Phylecia Jones, mathematician and educator Dan Finkel, math teacher Eddie Woo, educator Masha Gershman, and radio personality and eternal math nerd Adam Spencer.
Now Playing: Science for the People

#518 With Genetic Knowledge Comes the Need for Counselling
This week we delve into genetic testing - for yourself and your future children. We speak with Jane Tiller, lawyer and genetic counsellor, about genetic tests that are available to the public, and what to do with the results of these tests. And we talk with Noam Shomron, associate professor at the Sackler School of Medicine at Tel Aviv University, about technological advancements his lab has made in the genetic testing of fetuses.